Grants for County governments - Consumer Protection

FDA announces the availability of fiscal year (FY) 2024 funds to support one or more projects to 1) collect antimicrobial use data from diverse animal sectors, including domestic livestock, poultry, companion animals (dogs, cats, and horses), and minor species (e.g., fish, sheep, goats) and 2) contribute to the development of data collection frameworks, including providing data and expertise as resources and a public-private partnership frameworks are established. This grant will support the continued advancement of FDA;apos;s initiatives to support antimicrobial stewardship in veterinary settings. It will also support the National Action Plan objectives to engage the animal health community and relevant stakeholders to advance strategies intended to improve understanding of antimicrobial use and foster antimicrobial stewardship in animal agriculture.

The "Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required" grant aims to fund clinical trials that test the effectiveness and safety of new treatments for rare diseases, with the goal of increasing the number of approved treatments for these conditions.

The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemically pure form; 2) assessment of the biological activity of each stereo chemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs.

The ConnectALL Initiative's Municipal Infrastructure Program (MIP) is designed to foster the development of open-access, publicly owned, and/or controlled last-mile fiber broadband infrastructure. This initiative aims to deliver reliable high-speed internet services to homes, businesses, and community anchor institutions throughout New York State. The program's mission aligns directly with the New York State Urban Development Corporation d/b/a Empire State Development ("ESD") objectives to promote a vigorous and growing state economy, encourage business investment and job creation, and support diverse, prosperous local economies across NYS. By addressing broadband access, the MIP contributes to ESD's broader strategy of using grants and other forms of assistance to facilitate economic development and improve quality of life for residents. The target beneficiaries of the MIP include communities across New York State that are currently experiencing connectivity challenges due to a lack of affordable, high-speed internet infrastructure. Specifically, the program aims to connect homes, businesses, and community anchor institutions. The primary impact goal is to improve broadband access, thereby reducing the digital divide and enabling greater participation in the digital economy. Expected outcomes include a significant increase in the availability of reliable, high-speed internet, leading to enhanced economic opportunities, improved educational access, and better access to essential services for residents and businesses in underserved areas. The program's priorities and focuses revolve around the construction of new infrastructure or the acquisition of existing infrastructure. This includes last-mile fiber connections to address last-mile infrastructure (cabling, wires, pole replacements, radios) and drops to buildings. It also emphasizes fiber connections to Internet Exchange Points or Data Centers, including middle-mile fiber and networking equipment. A key focus is on ensuring open-access and predominantly publicly controlled infrastructure, leveraging funding from the U.S. Department of Treasury Capital Projects Fund (CPF) to achieve these objectives. The ConnectALL Initiative's strategic priorities are deeply rooted in addressing fundamental connectivity gaps across the state. The theory of change posits that by investing in publicly controlled, open-access fiber broadband infrastructure, the state can stimulate economic growth, create jobs, and foster more equitable access to information and opportunities. The expected measurable results include the deployment of new fiber optic networks, the number of homes, businesses, and community anchor institutions connected, and ultimately, an improvement in the overall broadband speed and affordability available to New Yorkers. The total funding available for this program is $228 Million, with a maximum grant size of $30 million per award, indicating a significant investment to achieve these transformative goals.

The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement. The proposed work directly supports the U.S. FDAs stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities. In addition to the work outlined above, the award recipient will assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.

This funding opportunity is designed to support businesses, organizations, and individuals in Vermont working to improve the competitiveness of specialty crops through various projects that benefit multiple stakeholders in the agricultural community.

Youth Service America's (YSA) "We Serve to Remember 9/11 Day of Service Grants" program is designed to empower young changemakers aged 5 to 25. This initiative directly aligns with YSA's mission of engaging youth in service and fostering active citizenship. The grants support organizations, schools, and youth changemakers in planning and implementing service activities that honor and pay tribute to those affected by 9/11. The program emphasizes youth leadership, ensuring that projects are driven by the young participants themselves, thereby developing their leadership skills and sense of community responsibility. The program's target beneficiaries are primarily youth, with a strong focus on engaging those who are not typically asked to serve and face systemic barriers to participation. This includes young people of color, youth from underserved low-income families and neighborhoods, and youth who are often beneficiaries of service rather than participants. Specific groups identified include youth in rural communities, those experiencing homelessness, youth in foster care, youth with disabilities, youth in the juvenile justice system, immigrants or refugees, youth from military families, LGBTQ+ youth, and English language learners. The impact goal is to create a more inclusive service environment and empower a diverse group of young people to contribute to their communities. A key priority of this grant program is the engagement of at least 100 youth volunteers per project, with 80% of these volunteers identifying as youth facing systemic barriers to participation. Projects must include elements to honor and pay tribute to those who lost their lives on 9/11, their families, and those who responded in service. All activities must take place on or around September 11th National Day of Service and Remembrance (September 11, 2024). This specific timing reinforces the program's focus on remembrance and national service. YSA expects to award up to 100 grants of $1,000 each. The expected outcomes include a significant increase in youth engagement in service, particularly among marginalized groups, and the successful execution of service activities that commemorate 9/11. Measurable results will include the number of grants awarded, the number of youth volunteers engaged, and the percentage of those volunteers who identify as facing systemic barriers. The program also aims to foster a sense of civic duty and historical awareness among participants. The foundation's strategic priorities are centered on youth empowerment and inclusive participation in service. YSA's theory of change posits that by providing resources and opportunities, particularly to underserved youth, they can develop leadership skills, strengthen communities, and create a lasting impact. By focusing on youth-led projects and ensuring diverse representation, YSA aims to build a generation of civically engaged individuals who are committed to addressing community needs and remembering significant historical events. Applicants must be based in the United States, with activities benefiting people in the U.S., including its territories. This geographical focus ensures that the grants support local communities across the nation. The emphasis on reaching youth who face systemic barriers aligns with a broader strategic goal of promoting equity and inclusion within the service sector, demonstrating YSA's commitment to a more representative and impactful youth service movement.

This Notice of Funding Opportunity (NOFO) invites applications for a cooperative agreement to support, manage and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. Projects are identified by FDA. Multiple awards may be funded under this NOFO and are directly dependent on drug development priorities and subject to the availability of funding.

This funding opportunity supports researchers in developing innovative tools that can speed up drug development and improve regulatory processes, ultimately enhancing public health by facilitating faster access to effective treatments.

Notice of Funding Opportunity Description Background The Food and Drug Administration (FDA) protects the public health by ensuring that medical products intended to be marketed in the United States are safe and effective for their intended use. FDA stakeholders are exploring innovative ways to produce scientific evidence in support of regulatory submissions, including the development of new data sources, study designs, methodologies, and technologies. FDA encourages and facilitates the use of such innovative approaches while ensuring that the scientific evidence supporting marketing approvals meet our high evidentiary standards. The Prescription Drug User Fee Act VII (PDUFA VII) commitment letter represents the product of discussions between the FDA, regulated industry, and public stakeholders, as mandated by Congress. The performance and procedural goals and other commitments specified in the PDUFA VII commitment letter apply to aspects of the human drug review program that are important for facilitating timely access to safe, effective, and innovative new medicines for patients. The commitment letter includes goals relating to the use of digital health technologies (DHTs) to support drug development and review. A DHT is a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. DHTs may rely on or work with other technologies that support their operation, such as general-purpose computing platforms (e.g., smartphones) and communication networks. Among other activities relating to the use of DHTs, FDA has established a Framework for the Use of DHTs in Drug and Biological Product Development to guide the use of DHT-derived data in regulatory decision-making for drugs (hereinafter Framework ). The Framework highlights FDA’s DHT efforts including workshops and demonstration projects; engagement with stakeholders; establishment of internal processes to support the evaluation of DHTs for use in drug development; promotion of shared learning and consistency regarding DHT-based policy, procedure, and analytic tool development; and publication of guidance documents. In addition, FDA’s webpage DHTs for Drug Development (available at: https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development) provides an overview of the ongoing DHT efforts, including demonstration projects. A variety of project types are welcomed under this NOFO, applicable to drugs and biologics (not devices). FDA is particularly interested in projects that evaluate the use of DHTs in drug development. Project Objectives The overarching goal of this notice of funding opportunity (NOFO) is to explore the role of DHTs (e.g., actigraphy, photography, environmental sensors) in the evaluation of new drugs. These projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups, and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on: Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of environmental sensors to capture apnea in pediatric patients) Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina) Capturing early manifestations of chronic diseases (e.g., dementia) through the use of DHTs

The purpose of the SNAP Fraud Framework Implementation Grant Program is to support State agency efforts to improve and expand recipient fraud prevention, detection, and investigation efforts using the procedures, ideas and practices outlined in the SNAP Fraud Framework.Organizational Management: This objective aims to help States establish and communicate priorities, organize employees, and manage both large-scale and day-to-day processes. Many of the concepts described in this component are the foundation for successful program integrity initiatives.Performance Measurement: This objective offers recommendations encouraging States to consistently capture and analyze their own performance.Recipient Integrity Education: This objective provides targeted integrity education initiatives to help ensure recipients have the necessary information and tools to use SNAP benefits as intendedpreventing fraud before it occurs. When producing recipient integrity education materials, States are encouraged to educate the public and applicants about SNAP fraud, rather than emphasize the consequences as a deterrent to applying.Fraud Detection: Here, the SNAP Fraud Framework stresses the importance of proactively detecting fraud from the application process and continuing throughout the recipients time in the Program.Investigations and Dispositions: This objective aims to provide states with tools and suggestions to improve fraud case management from initial fraud referral through disposition.Analytics and Data Management: This objective details the necessary people, processes, and technology to launch and maintain an analytics capability. Data analytics can play a valuable role in preventing, detecting, and investigating SNAP fraud.Learning and Development: The final objective contains recommendations for States to invest in training and professional development opportunities to promote employee engagement and to ensure employees are aware of new and emerging trends in fraud.Please read the entire request for applications (RFA) for additional information.

This funding opportunity supports clinical trials aimed at developing new therapies for rare neurodegenerative diseases, such as ALS, and is open to a wide range of eligible organizations, including universities and nonprofits.

This funding opportunity provides financial support to U.S.-based organizations, including universities, nonprofits, and businesses, to help outsourcing facilities produce critical medications that are in short supply and vulnerable to fraud.

This award recognizes and honors a South Dakota farmer who has significantly contributed to the production and promotion of specialty crops, encouraging innovation and mentorship within the local agricultural community.

The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance minority health and health equity objectives.Areas of interest include:Proposals that focus on advancing equity in clinical trials by supporting efforts to advance diversity in clinical trials, equitable data efforts by increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography, and equity of voices by increasing understanding of diverse patient perspectives, preferences, and unmet needs.

The Tobacco Grant Program, administered by the Office of the Attorney General, California Department of Justice, aims to foster a healthier California by curtailing illegal cigarette and tobacco sales and marketing to minors. This highly competitive program, enabled by Proposition 56, allocates funds to applicants with robust enforcement capabilities. Funded agencies will focus on enforcing tobacco-related laws, conducting retailer and online inspections, and enhancing local coordination and education efforts.

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.

The purpose of the funding opportunity is to expand and advance FDA's Office of Minority Health and Health Equity (OMHHE) work with stakeholders and partners for education, outreach, and public awareness activities on potential risks from skin lightening products containing hydroquinone and/or mercury.Applicants will research and propose innovative and community-based strategies and activities that have the potential to strengthen the science base for education and public health awareness on the use of and potential risks from over-the-counter (OTC) skin lightening products.

The FY24 BCRP Clinical Research Extension Award is designed to maximize the impact of previously funded breast cancer clinical studies by extending or expanding data collection, follow-up, and analysis. This mechanism directly addresses the loss of knowledge resulting from early trial termination, limited patient follow-up, or inadequate sample/data collection and analysis. The BCRP emphasizes the invaluable contributions of patient specimens and data, aiming to ensure that research maximizes the impact of these contributions toward saving lives and accelerating progress in ending breast cancer. Projects proposing to conduct new clinical trials will not be supported, focusing instead on leveraging existing clinical study infrastructure and data. The core impact goal of the award is to extend or affect the impact of a previously funded clinical trial or study, or to generate new impact toward ending breast cancer. Target beneficiaries include breast cancer patients whose contributions are utilized, and ultimately, active-duty Service Members, Veterans, military beneficiaries, and the American public who stand to benefit from advancements in breast cancer research. The program encourages collaborations between researchers at military/Veteran institutions and non-military institutions to leverage unique resources and access to diverse clinical populations, ensuring the research is relevant to the military community and the general public. Priorities and focuses for the proposed research, although not all-inclusive, include deeper molecular analysis of clinical samples, new correlative studies, biomarker validation, or continuing clinical follow-up of patients in open or completed trials. The research may be hypothesis-testing, -generating, or designed to create clinically annotated and molecularly characterized experimental platforms, such as patient-derived models. A required component is the involvement of two or more breast cancer consumer advocates—individuals diagnosed with breast cancer and active in advocacy organizations—who must provide objective input on the research design and its potential impact for individuals with, or at risk for, breast cancer. Innovation is not a required criterion for this award. Expected outcomes include generating meaningful hypotheses or supporting valid conclusions through statistically appropriate sample sizes and robust data analysis. Applicants must outline a data-sharing plan to ensure the scientific community has access to experimental platforms, molecular, and other data generated. The award encourages meaningful and productive partnerships, offering a Partnering PI Option with a higher funding limit ($6M vs. $5M for a single PI) to support collaborative efforts where both PIs bring distinct and critical expertise, reinforcing a strategic priority to foster team science in complex research questions. The CDMRP expects to allot approximately $18.6 million to fund about two applications.

The 2024-25 Physical and Digital Infrastructure Security Grant (DF) Program for Health Care Facilities, offered by the California Governor’s Office of Emergency Services (Cal OES), aims to enhance physical and digital security for healthcare facilities in California. This program aligns with the foundational mission of protecting vital health services and ensuring the safety of facilities that provide abortion-related and reproductive healthcare, which are often targets of violence and vandalism. The grant seeks to mitigate these threats, thereby supporting the continuity and accessibility of critical healthcare services across the state. The target beneficiaries of this grant are currently licensed community health centers, tribal health programs, non-profit hospitals not part of large health systems, and non-profit organizations whose membership includes such licensed facilities. All eligible applicants must be located in California and provide abortion-related services (or referrals) and reproductive healthcare services. The impact goal is to strengthen the security infrastructure of these facilities, creating safer environments for both patients and staff, and ensuring uninterrupted access to essential healthcare. The program's priorities and focuses include providing funding for physical facility enhancements, such as improved security measures for buildings, and digital security enhancements to protect against cyber threats and data breaches. The grant specifically targets facilities that may be vulnerable to violence and vandalism due to the nature of the services they provide. The funding aims to directly address these vulnerabilities, thereby safeguarding the operational capacity of these crucial healthcare providers. Expected outcomes and measurable results include a demonstrable improvement in the physical and digital security posture of funded facilities. This could involve a reduction in incidents of vandalism or violence, enhanced data protection, and increased patient and staff safety. The grant period is from September 1, 2024, through December 31, 2026, during which time facilities are expected to implement and integrate these security upgrades. Applicants can request up to $750,000 from the total available funding of $7,798,822. While specific "Foundation's strategic priorities and theory of change" are not explicitly detailed for Cal OES in the provided text, the underlying theory of change for this grant program appears to be that by providing targeted funding for security enhancements, the state can directly reduce risks to essential healthcare infrastructure. This proactive investment is expected to lead to greater resilience for healthcare facilities, particularly those offering sensitive services, thereby upholding public health and safety and ensuring that all Californians have access to necessary medical care without fear or disruption.